KLK3 and metastatic prostate carcinoma: They demonstrated that, while PSA screening and the age-adjusted incidence of diagnosis of metastatic prostate cancer in men 40 years or older varied between states, those states with greater decreases in PSA screening had increased incidence of metastatic prostate cancer diagnoses.